Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect Study of CKD-383 in Healthy Volunteers
NCT06492655Phase 1Not yet recruiting
- Sponsor
- Chong Kun Dang Holdings
- Start
- Jul 2024
- Primary completion
- Aug 2024
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of lobeglitazone + empagliflozin + metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Concentration-time Curve from time zero to the last measurable concentration and Maximum Plasma Concentration. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
lobeglitazone + empagliflozin + metformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06492655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06492655.